Single-agent Ibrutinib Therapy Provides Durable Response in CLL/SLL

Share this content:
Treatment with single-agent ibrutinib was well-tolerated in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Treatment with single-agent ibrutinib was well-tolerated in chronic lymphocytic leukemia/small lymphocytic lymphoma.

Treatment with single-agent ibrutinib was well-tolerated and provided durable responses among patients with treatment-naive or relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), according to a study published in Clinical Cancer Research.1

Researchers evaluated data from 94 patients with CLL/SLL, 27 of which were treatment-naive and 67 of which were relapsed/refractory. These patients were treated with ibrutinib at a dosage of 420 mg per day with 44 months of follow-up to determine the single-agent efficacy and tolerability of the drug.

The study found that treatment response was “rapid and durable” among these patients, with the best overall response being 91% among treatment-naive patients and 94% among relapsed/refractory patients. The progression-free survival rate at 30 months was 96% for treatment-naive patients and 76% for relapsed/refractory patients.

Treatment with ibrutinib was well-tolerated upon extended follow-up, with rates of discontinuations due to toxicities such as grade 3 or more cytopenias and fatigue decreasing over time.

RELATED: MRD Eradication With Alemtuzumab Consolidation Improves OS, PFS in CLL

Median duration of response and median progression-free survival were not reached.

The authors noted that 66% of patients enrolled in the study were continuing on ibrutinib therapy.

Reference

  1. Coutré SE, Furman RR, Flinn IW, et al. Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Can Research. 2017 Jan 10. doi: 10.1158/1078-0432.CCR-16-1431 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters